Q32 Bio (QTTB) Shares Outstanding (Weighted Average) (2017 - 2026)
Q32 Bio's quarterly Shares Outstanding (Weighted Average) came in at $14.1 million in Q1 2026, up 15.56% year-on-year from $12.2 million in Q1 2025, and up 14.59% quarter-over-quarter from $12.3 million in Q4 2025.
Q32 Bio has reported Shares Outstanding (Weighted Average) for 10 years, with the latest figure at $14.1 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 15.56% year-over-year to $14.1 million; the trailing twelve-month figure through Mar 2026 stood at $14.1 million (up 15.56% YoY), and the FY2025 full-year result was $12.3 million, up 31.97% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $14.1 million, up from $12.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $57.4 million in Q3 2022, with the low at $344623.0 in Q1 2023.
- Average Shares Outstanding (Weighted Average) over 5 years is $19.0 million, with a median of $12.2 million recorded in 2025.
- Year-over-year, Shares Outstanding (Weighted Average) plunged 99.4% in 2023 and surged 3387.39% in 2024.
- Tracing QTTB's Shares Outstanding (Weighted Average) over 5 years: stood at $57.4 million in 2022, then slumped by 99.39% to $349060.0 in 2023, then surged by 2570.28% to $9.3 million in 2024, then jumped by 31.97% to $12.3 million in 2025, then advanced by 14.59% to $14.1 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $14.1 million (Q1 2026), $12.3 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 14.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.10 Mn |
| Dec 31, 2025 | 12.30 Mn |
| Sep 30, 2025 | 12.24 Mn |
| Jun 30, 2025 | 12.20 Mn |
| Mar 31, 2025 | 12.20 Mn |
| Dec 31, 2024 | 9.32 Mn |
| Sep 30, 2024 | 12.08 Mn |
| Jun 30, 2024 | 6.48 Mn |
| Mar 31, 2024 | 995,280.00 |
| Dec 31, 2023 | 349,060.00 |
| Sep 30, 2023 | 346,288.00 |
| Jun 30, 2023 | 347,936.00 |
| Mar 31, 2023 | 344,623.00 |
| Dec 31, 2022 | 57.40 Mn |
| Sep 30, 2022 | 57.45 Mn |
| Jun 30, 2022 | 57.33 Mn |
| Mar 31, 2022 | 57.28 Mn |
| Dec 31, 2021 | 55.28 Mn |
| Sep 30, 2021 | 57.11 Mn |
| Jun 30, 2021 | 53.43 Mn |
| Mar 31, 2021 | 50.36 Mn |
| Dec 31, 2020 | 45.91 Mn |
| Sep 30, 2020 | 45.20 Mn |
| Jun 30, 2020 | 45.18 Mn |
| Mar 31, 2020 | 45.15 Mn |
| Dec 31, 2019 | 42.12 Mn |
| Sep 30, 2019 | 41.50 Mn |
| Jun 30, 2019 | 40.23 Mn |
| Mar 31, 2019 | 37.38 Mn |
| Dec 31, 2018 | 28.55 Mn |
| Sep 30, 2018 | 25.85 Mn |
| Jun 30, 2018 | 19.61 Mn |
| Mar 31, 2018 | 2.50 Mn |
| Dec 31, 2017 | 2.48 Mn |
| Sep 30, 2017 | 2.35 Mn |
| Jun 30, 2017 | 2.30 Mn |
| Mar 31, 2017 | 1.99 Mn |